No connection

Search Results

ADNT

BEARISH
$21.61 Live
Adient plc · NYSE
Target $25.05 (+15.9%)
$10.04 52W Range $26.16

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Jan 24, 2026
Market cap
$1.71B
P/E
N/A
ROE
-8.1%
Profit margin
-1.9%
Debt/Equity
1.23
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
78%
The Advanced Deterministic Scorecard reveals critical weaknesses in Adient plc's financial health, with a Piotroski F-Score of just 2/9 indicating severe operational and profitability concerns. Despite a low forward P/E of 7.11 and a price/book below 1, suggesting potential value, the company is unprofitable (negative net margin and ROE), highly leveraged (Debt/Equity of 1.23), and experiencing sharply declining earnings (YoY EPS down 23.5%, earnings growth -76.6%). Insider selling, inconsistent earnings beats (only 1 of last 4 quarters), and weak long-term price performance (-47.7% over 3 years) further undermine confidence. While analysts recommend a 'buy' with a $25.05 target, the fundamental fragility outweighs near-term optimism.

Key Strengths

Low forward P/E ratio of 7.11 suggests potential undervaluation relative to earnings potential
Price-to-Book of 0.97 indicates shares trade below book value, a traditional value signal
Revenue growth remains positive at 3.5% YoY, showing top-line resilience
Operating margin of 3.58% indicates some cost control at operational level
Analyst consensus recommendation is 'buy' with a 15.5% upside to target price

Key Risks

Piotroski F-Score of 2/9 signals very weak financial health and high risk of distress
Negative profit margin (-1.93%) and ROE (-8.14%) indicate persistent unprofitability
High Debt/Equity ratio of 1.23 increases financial risk, especially in downturns
Earnings growth collapsing: YoY down 76.6%, Q/Q down 77.2%
Insiders are selling: $0.32M in sales over last 6 months with no buys
AI Fair Value Estimate
Based on comprehensive analysis
$18.5
-14.4% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
28
Weak
Value
68
Future
24
Past
30
Health
18
Dividend
0
AI Verdict
High-risk turnaround play with speculative value appeal but weak fundamentals
Key drivers: Low valuation multiples, Negative earnings and profitability, Weak Piotroski score, Insider selling, Analyst optimism despite fundamentals
Confidence
80%
Value
68/100

Ref P/E, PEG, Graham Number

Positives
  • Forward P/E of 7.11 is well below sector average of 56.39
  • Price/Book of 0.97 suggests asset-backed floor
  • Price/Sales of 0.12 is extremely low, indicating deep value
Watchpoints
  • No Graham Number or intrinsic value provided
  • P/E is misleading due to negative earnings (trailing P/E N/A)
Future
24/100

Ref Growth rates

Positives
  • Revenue growth still positive at 3.5% YoY
  • Most recent Q/Q EPS growth was +15.6%, a short-term rebound
Watchpoints
  • Earnings growth YoY down 76.6%
  • Q/Q earnings growth down 77.2%
  • PEG ratio unavailable due to negative or volatile earnings
Past
30/100

Ref Historical trends

Positives
  • Some history of large earnings surprises (e.g., +108.4% in Q3 2023)
  • 1Y price return of +27.9% shows recent recovery
Watchpoints
  • Only 1 of last 4 quarters beat estimates
  • High earnings volatility and multiple large negative surprises
  • 3Y price return down 47.7%, indicating long-term underperformance
Health
18/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Current ratio of 1.12 shows minimal short-term liquidity
  • Operating margin positive at 3.58%
Watchpoints
  • Piotroski F-Score of 2/9 indicates severe financial weakness
  • ROE of -8.14% and negative net margin
  • Quick ratio of 0.81 indicates potential liquidity stress
  • Debt/Equity of 1.23 is high, especially for a cyclical sector
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • Dividend Strength score of 0/100
  • No dividend yield or payout history
  • Payout ratio is 0%, but no actual dividend paid

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$21.61
Analyst Target
$25.05
Upside/Downside
+15.9%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ADNT and closest competitors.

Updated 2026-01-23
ADN
Adient plc
Primary
5Y
-36.0%
3Y
-47.7%
1Y
+27.9%
6M
-4.9%
1M
+11.6%
1W
-1.9%
AIN
Albany International Corp.
Peer
5Y
-20.0%
3Y
-45.0%
1Y
-27.5%
6M
-19.5%
1M
+12.4%
1W
-0.5%
MCR
Monarch Casino & Resort, Inc.
Peer
5Y
+64.6%
3Y
+35.7%
1Y
+34.1%
6M
+3.3%
1M
-2.4%
1W
-0.2%
ARC
Arcos Dorados Holdings Inc.
Peer
5Y
+65.6%
3Y
+8.2%
1Y
-2.4%
6M
+15.5%
1M
-7.9%
1W
-3.9%
ACV
ACV Auctions Inc.
Peer
5Y
-72.8%
3Y
-8.0%
1Y
-61.5%
6M
-41.7%
1M
+2.9%
1W
-2.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
7.11
PEG Ratio
N/A
P/B Ratio
0.97
P/S Ratio
0.12
EV/Revenue
0.26
EV/EBITDA
4.99
Market Cap
$1.71B

Profitability

Profit margins and return metrics

Profit Margin -1.93%
Operating Margin 3.58%
Gross Margin 6.81%
ROE -8.14%
ROA 2.98%

Growth

Revenue and earnings growth rates

Revenue Growth +3.5%
Earnings Growth -76.6%
Q/Q Revenue Growth N/A
Q/Q Earnings Growth -77.2%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
1.23
Moderate
Current Ratio
1.12
Good
Quick Ratio
0.81
Poor
Cash/Share
$12.1

Quarterly Earnings History

EPS performance vs analyst estimates

2026-02-04
$N/A
2025-11-05
$0.52
-7.3% surprise
2025-08-06
$0.45
-6.9% surprise
2025-05-07
$0.69
+111.6% surprise

Consumer Cyclical Sector Comparison

Comparing ADNT against 237 companies in the Consumer Cyclical sector (12 bullish, 83 neutral, 142 bearish)
Return on Equity (ROE)
-8.14%
This Stock
vs
-38.9%
Sector Avg
-79.1% (Below Avg)
Profit Margin
-1.93%
This Stock
vs
-4.36%
Sector Avg
-55.7% (Weaker)
Debt to Equity
1.23
This Stock
vs
1.4
Sector Avg
-12.1% (Lower)
Revenue Growth
3.5%
This Stock
vs
16.59%
Sector Avg
-78.9% (Slower)
Current Ratio
1.12
This Stock
vs
2.5
Sector Avg
-55.2% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

DORLACK JEROME J
Chief Executive Officer
Stock Award
2025-12-31
14,866 shares
BERTHELIN MICHEL PIERRE ROSE
Officer
Sell
2025-11-26
2,500 shares · $49,275
HUANG JIAN JAMES
Officer
Stock Award
2025-11-17
3,667 shares
HUANG JIAN JAMES
Officer
Stock Award
2025-11-14
73,900 shares
DORLACK JEROME J
Chief Executive Officer
Stock Award
2025-11-13
220,324 shares
BERTHELIN MICHEL PIERRE ROSE
Officer
Stock Award
2025-11-13
4,685 shares
SMITH GREGORY SCOTT
Officer
Stock Award
2025-11-13
9,889 shares
TILTMANN HEATHER M
Officer
Stock Award
2025-11-13
49,589 shares
CONKLIN JAMES D.
Officer
Stock Award
2025-11-13
52,543 shares
OSWALD MARK A.
Chief Financial Officer
Stock Award
2025-11-13
60,848 shares
MARIANOS STEPHANIE S
Officer
Stock Award
2025-11-13
30,115 shares
DORLACK JEROME J
Chief Executive Officer
Sell
2025-08-07
12,000 shares · $273,240
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
10 analysts
Stifel
2026-01-23
Maintains
Buy Buy
Barclays
2026-01-23
Maintains
Equal-Weight Equal-Weight
UBS
2026-01-14
up
Neutral Buy
Wells Fargo
2026-01-12
Maintains
Overweight Overweight
Morgan Stanley
2025-12-08
up
Underweight Equal-Weight
Citigroup
2025-11-12
Maintains
Neutral Neutral
Barclays
2025-11-07
Maintains
Equal-Weight Equal-Weight
JP Morgan
2025-11-06
Maintains
Neutral Neutral
UBS
2025-11-06
Maintains
Neutral Neutral
Wells Fargo
2025-11-06
Maintains
Overweight Overweight

Past News Coverage

Recent headlines mentioning ADNT from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile